vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Sprout Social, Inc. (SPT). Click either name above to swap in a different company.
Sprout Social, Inc. is the larger business by last-quarter revenue ($120.9M vs $86.8M, roughly 1.4× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 12.9%). Sprout Social, Inc. produced more free cash flow last quarter ($9.9M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 11.8%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Sprout Social, Inc. is a technology company that runs a social media management platform. A public company headquartered in Chicago, it was founded in 2010 by Justyn Howard, Aaron Rankin, Gil Lara, and Peter Soung.
IOVA vs SPT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $120.9M |
| Net Profit | — | — |
| Gross Margin | 67.4% | 77.6% |
| Operating Margin | -84.7% | -9.0% |
| Net Margin | — | — |
| Revenue YoY | 17.7% | 12.9% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $120.9M | ||
| Q3 25 | $67.5M | $115.6M | ||
| Q2 25 | $60.0M | $111.8M | ||
| Q1 25 | $49.3M | $109.3M | ||
| Q4 24 | $73.7M | $107.1M | ||
| Q3 24 | $58.6M | $102.6M | ||
| Q2 24 | $31.1M | $99.4M | ||
| Q1 24 | $715.0K | $96.8M |
| Q4 25 | — | — | ||
| Q3 25 | $-91.3M | $-9.4M | ||
| Q2 25 | $-111.7M | $-12.0M | ||
| Q1 25 | $-116.2M | $-11.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-83.5M | $-17.1M | ||
| Q2 24 | $-97.1M | $-16.9M | ||
| Q1 24 | $-113.0M | $-13.6M |
| Q4 25 | 67.4% | 77.6% | ||
| Q3 25 | 43.0% | 77.7% | ||
| Q2 25 | 5.5% | 77.7% | ||
| Q1 25 | -0.8% | 77.3% | ||
| Q4 24 | 68.7% | 78.1% | ||
| Q3 24 | 46.2% | 77.4% | ||
| Q2 24 | -0.8% | 77.5% | ||
| Q1 24 | — | 76.8% |
| Q4 25 | -84.7% | -9.0% | ||
| Q3 25 | -140.7% | -7.9% | ||
| Q2 25 | -189.8% | -11.0% | ||
| Q1 25 | -245.8% | -10.2% | ||
| Q4 24 | -117.5% | -12.8% | ||
| Q3 24 | -152.1% | -16.4% | ||
| Q2 24 | -327.6% | -16.6% | ||
| Q1 24 | -16464.6% | -13.7% |
| Q4 25 | — | — | ||
| Q3 25 | -135.3% | -8.1% | ||
| Q2 25 | -186.2% | -10.7% | ||
| Q1 25 | -235.5% | -10.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | -142.7% | -16.6% | ||
| Q2 24 | -312.2% | -17.0% | ||
| Q1 24 | -15800.8% | -14.0% |
| Q4 25 | — | $-0.18 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | $-0.33 | $-0.21 | ||
| Q1 25 | $-0.36 | $-0.19 | ||
| Q4 24 | $-0.24 | $-0.25 | ||
| Q3 24 | $-0.28 | $-0.30 | ||
| Q2 24 | $-0.34 | $-0.30 | ||
| Q1 24 | $-0.42 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $95.3M |
| Total DebtLower is stronger | — | $40.0M |
| Stockholders' EquityBook value | $698.6M | $203.4M |
| Total Assets | $913.2M | $523.1M |
| Debt / EquityLower = less leverage | — | 0.20× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $95.3M | ||
| Q3 25 | $300.8M | $90.6M | ||
| Q2 25 | $301.2M | $101.5M | ||
| Q1 25 | $359.7M | $100.9M | ||
| Q4 24 | $323.8M | $86.4M | ||
| Q3 24 | $397.5M | $82.9M | ||
| Q2 24 | $412.5M | $80.9M | ||
| Q1 24 | $356.2M | $69.2M |
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $25.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $698.6M | $203.4M | ||
| Q3 25 | $702.3M | $194.1M | ||
| Q2 25 | $698.5M | $184.6M | ||
| Q1 25 | $767.9M | $175.3M | ||
| Q4 24 | $710.4M | $166.6M | ||
| Q3 24 | $773.5M | $158.1M | ||
| Q2 24 | $768.5M | $152.1M | ||
| Q1 24 | $680.0M | $147.3M |
| Q4 25 | $913.2M | $523.1M | ||
| Q3 25 | $904.9M | $481.4M | ||
| Q2 25 | $907.4M | $422.9M | ||
| Q1 25 | $966.7M | $424.7M | ||
| Q4 24 | $910.4M | $428.3M | ||
| Q3 24 | $991.1M | $388.8M | ||
| Q2 24 | $964.3M | $393.6M | ||
| Q1 24 | $869.8M | $389.9M |
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $10.9M |
| Free Cash FlowOCF − Capex | $-61.9M | $9.9M |
| FCF MarginFCF / Revenue | -71.3% | 8.2% |
| Capex IntensityCapex / Revenue | 10.7% | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $39.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $10.9M | ||
| Q3 25 | $-78.7M | $9.3M | ||
| Q2 25 | $-67.4M | $5.1M | ||
| Q1 25 | $-103.7M | $18.1M | ||
| Q4 24 | $-73.3M | $4.1M | ||
| Q3 24 | $-59.0M | $9.0M | ||
| Q2 24 | $-98.4M | $2.1M | ||
| Q1 24 | $-122.3M | $11.2M |
| Q4 25 | $-61.9M | $9.9M | ||
| Q3 25 | $-89.5M | $8.5M | ||
| Q2 25 | $-74.9M | $4.2M | ||
| Q1 25 | $-109.9M | $16.7M | ||
| Q4 24 | $-77.5M | $3.3M | ||
| Q3 24 | $-61.3M | $8.5M | ||
| Q2 24 | $-98.9M | $1.6M | ||
| Q1 24 | $-126.5M | $10.1M |
| Q4 25 | -71.3% | 8.2% | ||
| Q3 25 | -132.7% | 7.4% | ||
| Q2 25 | -124.9% | 3.7% | ||
| Q1 25 | -222.8% | 15.3% | ||
| Q4 24 | -105.1% | 3.0% | ||
| Q3 24 | -104.6% | 8.3% | ||
| Q2 24 | -317.9% | 1.6% | ||
| Q1 24 | -17685.3% | 10.4% |
| Q4 25 | 10.7% | 0.9% | ||
| Q3 25 | 16.1% | 0.7% | ||
| Q2 25 | 12.4% | 0.8% | ||
| Q1 25 | 12.6% | 1.2% | ||
| Q4 24 | 5.7% | 0.8% | ||
| Q3 24 | 3.9% | 0.5% | ||
| Q2 24 | 1.4% | 0.5% | ||
| Q1 24 | 583.4% | 1.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
SPT
Segment breakdown not available.
